Twelve months outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: observational study data

被引：0
|
作者：
Gillies, Mark C. [1 ]
Walton, Richard [1 ]
Arnold, Jennifer [2 ]
Essex, Rohan [3 ]
Morlet, Nigel [4 ]
Barthelmes, Daniel [1 ,5 ]
机构：
[1] Univ Sydney, Ophthalmol, Sydney, NSW, Australia
[2] Marsden Eye Specialists, Parramatta, NSW, Australia
[3] Canberra Hosp, Dept Ophthalmol, Garran, ACT, Australia
[4] Univ Western Australia, Dept Populat Hlth, Perth, WA, Australia
[5] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2016年 / 57卷 / 12期
基金：
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
523
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Ranibizumab in neovascular age-related macular degeneration
    Eng, Kenneth T.
    Kertes, Peter J.
    CLINICAL INTERVENTIONS IN AGING, 2006, 1 (04) : 451 - 466
  • [22] RANIBIZUMAB VERSUS AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: DATA FROM A PROSPECTIVE OBSERVATIONAL STUDY
    Barthelmes, Daniel
    Vaze, Anagha
    Vuong Nguyen
    Daien, Vincent
    Arnold, Jennifer J.
    Young, Stephanie H.
    Morlet, Nigel
    Gillies, Mark C.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [23] Twelve months outcomes of Intravitreal aflibercept for neovascular age-related macular degeneration. Fixed versus as needed dosing.
    Veritti, Daniele
    Ricci, Federico Ugo
    Sarao, Valentina
    Lanzetta, Paolo
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [24] Twelve-Month Outcomes of "Treat and Extend" aflibercept Therapy for Neovascular Age-Related Macular Degeneration
    Barthelmes, Daniel
    Vuong Nguyen
    Arnold, Jennifer
    McAllister, Ian
    Guymer, Robyn
    Essex, Rohan
    Young, Stephanie
    Gillies, Mark C.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [25] Effects of Intravitreal Aflibercept on Neovascular Age-Related Macular Degeneration Resistant to Intravitreal Ranibizumab
    Suzuki, Katsuya
    Yasukawa, Tsutomu
    Kato, Aki
    Fujino, Shinpei
    Morita, Hiroshi
    Ota, Satoshi
    Hirahara, Shuichiro
    Munenori, Yoshida
    Ogura, Yuichiro
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [26] Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
    Garweg, Justus G.
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 1289 - 1295
  • [27] Intravitreal aflibercept for neovascular age-related macular degeneration
    Xu, David
    Kaiser, Peter K.
    IMMUNOTHERAPY, 2013, 5 (02) : 121 - 130
  • [28] AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Verner-Cole, E. A.
    Davis, S. J.
    Lauer, A. K.
    DRUGS OF TODAY, 2012, 48 (05) : 317 - 329
  • [29] Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration
    Salabati, Mirataollah
    Obeid, Anthony
    Mahmoudzadeh, Raziyeh
    Gupta, Omesh
    Chiang, Allen
    Spirn, Marc
    Klufas, Michael A.
    Hsu, Jason
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (08) : 2509 - 2516
  • [30] Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration
    Mirataollah Salabati
    Anthony Obeid
    Raziyeh Mahmoudzadeh
    Omesh Gupta
    Allen Chiang
    Marc Spirn
    Michael A. Klufas
    Jason Hsu
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 2509 - 2516
12345